Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to Oseltamivir
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Influenza
Conditions
Influenza
Trial Timeline
Dec 8, 2016 → Apr 24, 2017
NCT ID
NCT02954354About Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to Oseltamivir
Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to Oseltamivir is a phase 3 stage product being developed by Shionogi for Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT02954354. Target conditions include Influenza.
What happened to similar drugs?
20 of 20 similar drugs in Influenza were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02949011 | Phase 3 | Completed |
| NCT02954354 | Phase 3 | Completed |
Competing Products
20 competing products in Influenza
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1010 | Moderna | Phase 1 | 0 |
| mRNA-1273 | Moderna | Phase 1 | 0 |
| mRNA-1010 | Moderna | Phase 2 | 0 |
| mRNA-1083 Composition 1 Dose A Lot A | Moderna | Phase 2 | 0 |
| mRNA-1010 | Moderna | Phase 3 | 0 |
| mRNA-1011.1 | Moderna | Phase 2 | 0 |
| mRNA-1083.1 | Moderna | Phase 2 | 0 |
| mRNA-1010 | Moderna | Phase 3 | 0 |
| mRNA-1083 | Moderna | Phase 3 | 0 |
| mRNA-1073 | Moderna | Phase 2 | 0 |
| VAL-506440 | Moderna | Phase 1 | 0 |
| mRNA-1083 | Moderna | Phase 3 | 0 |
| mRNA-1083 | Moderna | Phase 2 | 0 |
| mRNA-1010 | Moderna | Phase 3 | 0 |
| VAL-339851 | Moderna | Phase 1 | 0 |
| mRNA-1018-H5 | Moderna | Phase 3 | 0 |
| mRNA-1653 | Moderna | Phase 1 | 0 |
| mRNA-1030 | Moderna | Phase 2 | 0 |
| mRNA-1018 for H5N8 | Moderna | Phase 2 | 0 |
| mRNA-1653 | Moderna | Phase 1 | 0 |